+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Irritable Bowel Syndrome Treatment Market by Type, IBS with Constipation, and Mixed IBS, Product, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5021815
  • Report
  • January 2020
  • Region: Global
  • 250 pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • GlaxoSmithKline Plc
  • MORE
The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026. Irritable bowel syndrome is a gastrointestinal disorder of gut that may be identified by colon muscle contraction. It majorly affects the large intestine. In addition, it is associated with the malfunction of the bowel, and majorly occurs in geriatric population. Diarrhea, constipation, alteration & discomfort in bowel function, bloating, and abdominal pain are some of the common symptoms of irritable bowel syndrome. Endoscopy and blood test are normally performed to detect this irritable bowel syndrome. Irritable bowel syndrome is classified into three types such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS. Treatment of irritable bowel syndrome include proper medicines, change in diet, stress relief, and counseling. Medicines used in the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others.



Significant increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, abdominal pain, adoption of sedentary lifestyle, increase in level of stress, and unhealthy diet are the key factors that fuel the growth of the irritable bowel syndrome treatment market. According to the International Foundation for Gastrointestinal Disorders (IFFGD), it was estimated that irritable bowel syndrome affects around 25-45 million in the U.S. in 2016. Moreover, company developing products with symptom specific application and subsequent launches, increase in geriatric population, and rise in awareness programs for irritable bowel syndrome treatment are other factors that contribute toward the growth of the market. Furthermore, rise in prevalence of irritable bowel syndrome in female is expected to further boost the growth of global irritable bowel treatment market during the forecast period. However, high competition among the key players related to pricing and lack of specific treatment which treat all the symptoms of this disorder are expected to hinder the growth of the market.

The irritable bowel syndrome treatment market is segmented into type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. On the basis of product, the market is classified into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. On the basis of end user, the market is divided into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Type
  • IBS with Diarrhea (IBS-D)
  • IBS with Constipation (IBS-C)
  • Mixed IBS
By Product
  • Rifaximin
  • Eluxadoline
  • Lubiprostone
  • Linaclotide
  • Others
By End User
  • Hospitals Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abbott Laboratories
  • Allergan plc
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson (McNeil Consumer Healthcare)
  • Novartis AG
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Bausch Health
  • Synthetic Biologics, Inc.
  • Callisto Pharmaceuticals, Inc. (Synergy Pharmaceuticals)
  • Ironwood Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • GlaxoSmithKline Plc
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter's Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise In Geriatric Population
3.4.1.2. Rise In Prevalence of Gastrointestinal Disorders
3.4.1.3. Increase In Number of Pipeline Drugs
3.4.2. restraints
3.4.2.1. Poor Demand In Under Developed Countries
3.4.3. Opportunities
3.4.3.1. Untapped Opportunities In Developing Economies
3.4.4. Impact Analysis

Chapter 4: Irritable Bowel Syndrome Treatment Market, By Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Ibs With Diarrhea (Ibs-D)
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Ibs With Constipation (Ibs-C)
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Mixed-Presentation Ibs (Ibs-M)
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country

Chapter 5: Irritable Bowel Syndrome Treatment Market, By Product
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Rifaximin
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Eluxadoline
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
5.4. Lubiprostone
5.4.1. Market Size And Forecast
5.4.2. Market Analysis, By Country
5.5. Linaclotide
5.5.1. Market Size And Forecast
5.5.2. Market Analysis, By Country
5.6. Others
5.6.1. Market Size And Forecast
5.6.2. Market Analysis, By Country

Chapter 6: Irritable Bowel Syndrome Treatment Market, By End User
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospitals Pharmacies
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Drug Stores And Retail Pharmacies
6.3.1. Market Size And Forecast
6.3.2. Market Analysis, By Country
6.4. Online Pharmacies
6.4.1. Market Size And Forecast
6.4.2. Market Analysis, By Country

Chapter 7: Irritable Bowel Syndrome Treatment Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Irritable Bowel Syndrome Treatment Market, By Type
7.2.2.1.2. U.S. Irritable Bowel Syndrome Treatment Market, By Product
7.2.2.1.3. U.S. Irritable Bowel Syndrome Treatment Market, By End User
7.2.2.2. Canada
7.2.2.2.1. Canada Irritable Bowel Syndrome Treatment Market, By Type
7.2.2.2.2. Canada Irritable Bowel Syndrome Treatment Market, By Product
7.2.2.2.3. Canada Irritable Bowel Syndrome Treatment Market, By End User
7.2.2.3. Mexico
7.2.2.3.1. Mexico Irritable Bowel Syndrome Treatment Market, By Type
7.2.2.3.2. Mexico Irritable Bowel Syndrome Treatment Market, By Product
7.2.2.3.3. Mexico Irritable Bowel Syndrome Treatment Market, By End User
7.2.3. North America Market Size And Forecast, By Type
7.2.4. North America Market Size And Forecast, By Product
7.2.5. North America Market Size And Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.2.1. Germany
7.3.2.1.1. Germany Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.1.2. Germany Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.1.3. Germany Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.2. France
7.3.2.2.1. France Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.2.2. France Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.2.3. France Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.3. UK
7.3.2.3.1. UK Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.3.2. UK Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.3.3. UK Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.4. Italy
7.3.2.4.1. Italy Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.4.2. Italy Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.4.3. Italy Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.5. Spain
7.3.2.5.1. Spain Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.5.2. Spain Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.5.3. Spain Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.6.2. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.6.3. Rest of Europe Irritable Bowel Syndrome Treatment Market, By End User
7.3.3. Europe Market Size And Forecast, By Type
7.3.4. Europe Market Size And Forecast, By Product
7.3.5. Europe Market Size And Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.2.1. Japan
7.4.2.1.1. Japan Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.1.2. Japan Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.1.3. Japan Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.2. China
7.4.2.2.1. China Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.2.2. China Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.2.3. China Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.3. Australia
7.4.2.3.1. Australia Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.3.2. Australia Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.3.3. Australia Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.4. India
7.4.2.4.1. India Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.4.2. India Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.4.3. India Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.5. South Korea
7.4.2.5.1. South Korea Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.5.2. South Korea Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.5.3. South Korea Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.6.2. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.6.3. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By End User
7.4.3. Asia-Pacific Market Size And Forecast, By Type
7.4.4. Asia-Pacific Market Size And Forecast, By Product
7.4.5. Asia-Pacific Market Size And Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.1.2. Brazil Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.1.3. Brazil Irritable Bowel Syndrome Treatment Market, By End User
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.2.2. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.2.3. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By End User
7.5.2.3. South Africa
7.5.2.3.1. South Africa Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.3.2. South Africa Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.3.3. South Africa Irritable Bowel Syndrome Treatment Market, By End User
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.4.2. Rest of LAMEA Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.4.3. Rest of LAMEA Irritable Bowel Syndrome Treatment Market, By End User
7.5.3. LAMEA Market Size And Forecast, By Type
7.5.4. LAMEA Market Size And Forecast, By Product
7.5.5. LAMEA Market Size And Forecast, By End User

Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Allergan Plc
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments
8.3. Ardelyx Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments
8.4. Astellas Pharma Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves And Developments
8.5. Astrazeneca Plc
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Glaxosmithkline Plc
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Johnson & Johnson (Mcneil Consumer Healthcare)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Novartis Ag
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments
8.9. Sebela Pharmaceuticals Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.10. Takeda Pharmaceutical Company Ltd.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergan plc
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • GlaxoSmithKline Plc
  • MORE
According to the report, titled, 'Irritable Bowel Syndrome Treatment Market by Type, Product, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global irritable bowel syndrome treatment market size was valued at $ 1,071 million in 2018, and is projected to reach $2,012 million by 2026, growing at a CAGR of 8.2% from 2019 to 2026.

Irritable bowel syndrome is a gastrointestinal tract (GT) illness with the symptoms such as alteration of bowel habits and severe abdominal pain. Usually, the digested food passes through the gastrointestinal tract (GT) and the movement of food is due to intestinal muscle contraction. The irritable bowel syndrome hinders natural movements of that muscle; thus, food material cannot pass through the digestive tract and may result in abdominal pain, diarrhea, mucus in the stool, constipation, bloating & gas, and cramping. The Centers for Disease Control and Prevention (CDC) suggested that nearly 3 million people in the U.S. were reported being treated with irritable bowel syndrome in 2015. The irritable bowel syndrome can be treated by making changes by proper medication, making changes in daily diet, and reducing stress.

The major factors that boost the growth of the global irritable bowel syndrome treatment market are adoption of sedentary lifestyle, rise in level of stress, unhealthy diet, rise in geriatric population, surge in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, & abdominal pain, increase in awareness programs for irritable bowel syndrome treatment, and launches of various developed pipeline drugs for the irritable bowel syndrome treatment during the forecast period. Moreover, increase in prevalence of irritable bowel syndrome in female is expected to further drive the growth of the global irritable bowel treatment market. However, lack of specific treatment which treat all the symptoms of this disorder, and high competition among the key players related to pricing are expected to restrain the irritable bowel syndrome treatment market growth.

Depending on type, the IBS with diarrhea (IBS-D) segment dominated the irritable bowel syndrome treatment market in 2018 due to rise in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit and abdominal pain, rise in level of stress, and unhealthy diet.

By product, the rifaximin segment accounted for the highest revenue share in the irritable bowel syndrome treatment market in 2018, and is expected to maintain its dominance during the forecast period. This is attributed to adoption of sedentary lifestyle and rise in geriatric population. In addition, launches of various developed pipeline drugs for the irritable bowel syndrome treatment and rise in awareness programs are expected to offer remunerative opportunities for market expansion in the near future.

Key Findings of the Study
Based on type, the IBS with diarrhea (IBS-D) segment held 47.76% share in the global market in 2018.
Based on product, the rifaximin segment accounted for the largest irritable bowel syndrome treatment market share in 2018 and is expected to remain dominant throughout the forecast period.
Based on end user, the drug stores & retail pharmacies segment held 54.01% share in the global market in 2018.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.9% during the forecast period.
In 2018, North America accounted for the major share in the irritable bowel syndrome market size and is expected to continue this trend, owing to availability of well-developed infrastructure facilities, presence of majority of the key players, rise in gastrointestinal diseases, and huge availability of trained medical professionals. On the other hand, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to rise in disposable income, high population base, surge in the geriatric population, and an increase in patient awareness toward irritable bowel syndrome treatment.
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Allergan plc
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson (McNeil Consumer Healthcare)
  • Novartis AG
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Ltd.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll